On February 13, 2018, Mallinckrodt closed on our acquisition of Sucampo Pharmaceuticals, Inc. Full details are available in the press release found here. We welcome our new colleagues to Mallinckrodt.
Mallinckrodt is committed to the continued commercialization of AMITIZA® (lubiprostone) and to advancing its supplemental New Drug Application under review by the U.S. Food and Drug Administration assessing the drug’s safety and efficacy in children 6 to 17 years of age with pediatric functional constipation. To learn more about AMITIZA and its approved indications in the U.S., visit www.amitiza.com. For more on AMITIZA use in Japan, click here. We are also committed to continued commercialization of Rescula® (unoprostone isopropyl) in Japan.
We are excited and equally committed to continuing Sucampo’s strong efforts to bring much-needed development therapies to patients suffering from rare diseases like Niemann-Pick Type C and Familial Adenomatous Polyposis.
To learn more about our development products VTS-270 and CPP-1X/sulindac, visit our pipeline page.
Additional information regarding VTS-270 and Niemann-Pick Disease Type C (NPC) can be found at www.vtessepharma.com.
To access Sucampo's filings with the U.S. Securities and Exchange Commission, or to see its Governance Documents, click here.
Learn more about Mallinckrodt here.